Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
We investigated the contributions of the structural proteins of severe acute respiratory syndrome (SARS) coronavirus (CoV) to protective immunity by expressing them individually and in combinations from a recombinant parainfluenza virus (PIV) type 3 vector called BHPIV3. This vector provided direct immunization of the respiratory tract, the major site of SARS transmission, replication, and disease. The BHPIV3/SARS recombinants were evaluated for immunogenicity and protective efficacy in hamsters, which support a high level of pulmonary SARS-CoV replication. A single intranasal administration of BHPIV3 expressing the SARS-CoV spike protein (S) induced a high titer of SARS-CoV-neutralizing serum antibodies, only 2-fold less than that induced by SARS-CoV infection. The expression of S with the two other putative virion envelope proteins, the matrix M and small envelope E proteins, did not augment the neutralizing antibody response. In absence of S, expression of M and E or the nucleocapsid protein N did not induce a detectable serum SARS-CoV-neutralizing antibody response. Immunization with BHPIV3 expressing S provided complete protection against SARS-CoV challenge in the lower respiratory tract and partial protection in the upper respiratory tract. This was augmented slightly by coexpression with M and E. Expression of M, E, or N in the absence of S did not confer detectable protection. These results identify S among the structural proteins as the only significant SARS-CoV neutralization antigen and protective antigen and show that a single mucosal immunization is highly protective in an experimental animal that supports efficient replication of SARS-CoV.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A simple method of estimating 50 per cent end points
Muench, H. (1938) · Medical Entomology and Zoology · Cited by 8,376
Lipid rafts and signal transduction
Simons, K., & Toomre, D. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35036052 · Cited by 5,371
An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs
Kozak, M. (1987) · Nucleic Acids Research · doi:10.1093/nar/15.20.8125 · Cited by 5,087
Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Rota, P. A., Oberste, M. S., Monroe, S. S., Nix, W. A., Campagnoli, R., Icenogle, J. P., Peñaranda, S., Bankamp, B., Maher, K., Chen, M.-H., et al. (2003) · Science · doi:10.1126/science.1085952 · Cited by 2,474
The Genome Sequence of the SARS-Associated Coronavirus
Marra, M. A., Jones, S. J. M., Astell, C. R., Holt, R. A., Brooks-Wilson, A., Butterfield, Y. S. N., Khattra, J., Asano, J. K., Barber, S. A., Chan, S. Y., et al. (2003) · Science · doi:10.1126/science.1085953 · Cited by 2,026
Lipid Domain Structure of the Plasma Membrane Revealed by Patching of Membrane Components
Harder, T., Scheiffele, P., Verkade, P., & Simons, K. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.141.4.929 · Cited by 1,184
Buchholz, U. J., Finke, S., & Conzelmann, K.-K. (1999) · Journal of Virology · doi:10.1128/jvi.73.1.251-259.1999 · Cited by 1,034
Self-citationVennema, H., Godeke, G. J., Rossen, J. W., Voorhout, W. F., Horzinek, M. C., Opstelten, D. J., & Rottier, P. J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00553.x · Cited by 469
Subbarao, K., McAuliffe, J., Vogel, L., Fahle, G., Fischer, S., Tatti, K., Packard, M., Shieh, W.-J., Zaki, S., & Murphy, B. (2004) · Journal of Virology · doi:10.1128/jvi.78.7.3572-3577.2004 · Cited by 406
Self-citationVennema, H., de Groot, R. J., Harbour, D. A., Dalderup, M., Gruffydd-Jones, T., Horzinek, M. C., & Spaan, W. J. (1990) · Journal of Virology · doi:10.1128/jvi.64.3.1407-1409.1990 · Cited by 277
Cited by
COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses
Shereen, M. A., Khan, S., Kazmi, A., Bashir, N., & Siddique, R. (2020) · Journal of Advanced Research · doi:10.1016/j.jare.2020.03.005 · Cited by 3,536
Coronavirus biology and replication: implications for SARS-CoV-2
V’kovski, P., Kratzel, A., Steiner, S., Stalder, H., & Thiel, V. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00468-6 · Cited by 3,197
Coronavirus Disease 2019–COVID-19
Dhama, K., Khan, S., Tiwari, R., Sircar, S., Bhat, S., Malik, Y. S., Singh, K. P., Chaicumpa, W., Bonilla-Aldana, D. K., & Rodriguez-Morales, A. J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00028-20 · Cited by 1,876
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,661
Structure-based design of prefusion-stabilized SARS-CoV-2 spikes
Hsieh, C.-L., Goldsmith, J. A., Schaub, J. M., DiVenere, A. M., Kuo, H.-C., Javanmardi, K., Le, K. C., Wrapp, D., Lee, A. G., Liu, Y., et al. (2020) · Science · doi:10.1126/science.abd0826 · Cited by 1,303
Liu, C., Zhou, Q., Li, Y., Garner, L. V., Watkins, S. P., Carter, L. J., Smoot, J., Gregg, A. C., Daniels, A. D., Jervey, S., et al. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00272 · Cited by 1,297
Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome Coronavirus
Weiss, S. R., & Navas-Martin, S. (2005) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.69.4.635-664.2005 · Cited by 1,256
Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection
Cheng, V. C. C., Lau, S. K. P., Woo, P. C. Y., & Yuen, K. Y. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00023-07 · Cited by 1,192
Severe acute respiratory syndrome
Peiris, J. S. M., Guan, Y., & Yuen, K. Y. (2004) · Nature Medicine · doi:10.1038/nm1143 · Cited by 1,139
Zimmermann, P., & Curtis, N. (2020) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000002660 · Cited by 1,077
Immunological considerations for COVID-19 vaccine strategies
Jeyanathan, M., Afkhami, S., Smaill, F., Miller, M. S., Lichty, B. D., & Xing, Z. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00434-6 · Cited by 1,015
The Coronavirus Nucleocapsid Is a Multifunctional Protein
McBride, R., Van Zyl, M., & Fielding, B. (2014) · Viruses · doi:10.3390/v6082991 · Cited by 942
A decade after SARS: strategies for controlling emerging coronaviruses
Graham, R. L., Donaldson, E. F., & Baric, R. S. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3143 · Cited by 655
Dhama, K., Sharun, K., Tiwari, R., Dadar, M., Malik, Y. S., Singh, K. P., & Chaicumpa, W. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1735227 · Cited by 623
ter Meulen, J., van den Brink, E. N., Poon, L. L. M., Marissen, W. E., Leung, C. S. W., Cox, F., Cheung, C. Y., Bakker, A. Q., Bogaards, J. A., van Deventer, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030237 · Cited by 612
Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients
Suthar, M. S., Zimmerman, M. G., Kauffman, R. C., Mantus, G., Linderman, S. L., Hudson, W. H., Vanderheiden, A., Nyhoff, L., Davis, C. W., Adekunle, O., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100040 · Cited by 508
“, and 226 Collins, P.L. (2004). Contributions of the structural proteins of severe acute respiratory 227 syndrome coronavirus to protective immunity.”
Platelets Can Associate With SARS-CoV-2 RNA and Are Hyperactivated in COVID-19
Zaid, Y., Puhm, F., Allaeys, I., Naya, A., Oudghiri, M., Khalki, L., Limami, Y., Zaid, N., Sadki, K., Ben El Haj, R., et al. (2020) · Circulation Research · doi:10.1161/circresaha.120.317703 · Cited by 496
Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients
Sun, B., Feng, Y., Mo, X., Zheng, P., Wang, Q., Li, P., Peng, P., Liu, X., Chen, Z., Huang, H., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1762515 · Cited by 473
Coronavirus vaccine development: from SARS and MERS to COVID-19
Li, Y.-D., Chi, W.-Y., Su, J.-H., Ferrall, L., Hung, C.-F., & Wu, T.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00695-2 · Cited by 453
Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses
Wang, N., Shang, J., Jiang, S., & Du, L. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00298 · Cited by 425
Serological assays for emerging coronaviruses: Challenges and pitfalls
Meyer, B., Drosten, C., & Müller, M. A. (2014) · Virus Research · doi:10.1016/j.virusres.2014.03.018 · Cited by 410
Vulnerabilities in coronavirus glycan shields despite extensive glycosylation
Watanabe, Y., Berndsen, Z. T., Raghwani, J., Seabright, G. E., Allen, J. D., Pybus, O. G., McLellan, J. S., Wilson, I. A., Bowden, T. A., Ward, A. B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16567-0 · Cited by 379
COVID-19 vaccines: The status and perspectives in delivery points of view
Chung, J. Y., Thone, M. N., & Kwon, Y. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.011 · Cited by 375
“strong N-specific humoral and cellular immune responses [54], while others showed insignificant contribution of the N protein to production of neutralizing antibodies [55].”
BackgroundResultYu, F., Du, L., Ojcius, D. M., Pan, C., & Jiang, S. (2020) · Microbes and Infection · doi:10.1016/j.micinf.2020.01.003 · Cited by 366
Eosinophil responses during COVID-19 infections and coronavirus vaccination
Lindsley, A. W., Schwartz, J. T., & Rothenberg, M. E. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.04.021 · Cited by 354
Distinct Early Serological Signatures Track with SARS-CoV-2 Survival
Atyeo, C., Fischinger, S., Zohar, T., Slein, M. D., Burke, J., Loos, C., McCulloch, D. J., Newman, K. L., Wolf, C., Yu, J., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.020 · Cited by 349
“However, immunization of hamsters with a vector expressing N offered no protection against SARS-CoV-2 challenge despite a strong anti-N response, whereas immunization with the same vector expressing S protected hamsters against challenge (Buchholz et al., 2004).”
Liang, Y., Wang, M.-L., Chien, C.-S., Yarmishyn, A. A., Yang, Y.-P., Lai, W.-Y., Luo, Y.-H., Lin, Y.-T., Chen, Y.-J., Chang, P.-C., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01022 · Cited by 339
Neutralizing antibody titres in SARS-CoV-2 infections
Lau, E. H. Y., Tsang, O. T. Y., Hui, D. S. C., Kwan, M. Y. W., Chan, W.-H., Chiu, S. S., Ko, R. L. W., Chan, K. H., Cheng, S. M. S., Perera, R. A. P. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20247-4 · Cited by 333
Lessons for COVID-19 immunity from other coronavirus infections
Sariol, A., & Perlman, S. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.005 · Cited by 317
Jaume, M., Yip, M. S., Cheung, C. Y., Leung, H. L., Li, P. H., Kien, F., Dutry, I., Callendret, B., Escriou, N., Altmeyer, R., et al. (2011) · Journal of Virology · doi:10.1128/jvi.00671-11 · Cited by 314
Evaluation of candidate vaccine approaches for MERS-CoV
Wang, L., Shi, W., Joyce, M. G., Modjarrad, K., Zhang, Y., Leung, K., Lees, C. R., Zhou, T., Yassine, H. M., Kanekiyo, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms8712 · Cited by 299
Self-citationProgress and Prospects on Vaccine Development against SARS-CoV-2
Zhang, J., Zeng, H., Gu, J., Li, H., Zheng, L., & Zou, Q. (2020) · Vaccines · doi:10.3390/vaccines8020153 · Cited by 282
Deming, D., Sheahan, T., Heise, M., Yount, B., Davis, N., Sims, A., Suthar, M., Harkema, J., Whitmore, A., Pickles, R., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030525 · Cited by 275
Nal, B., Chan, C., Kien, F., Siu, L., Tse, J., Chu, K., Kam, J., Staropoli, I., Crescenzo-Chaigne, B., Escriou, N., et al. (2005) · Journal of General Virology · doi:10.1099/vir.0.80671-0 · Cited by 272
Martin, J. E., Louder, M. K., Holman, L. A., Gordon, I. J., Enama, M. E., Larkin, B. D., Andrews, C. A., Vogel, L., Koup, R. A., Roederer, M., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.09.026 · Cited by 267
Fc receptors in antibody‐dependent enhancement of viral infections
Taylor, A., Foo, S., Bruzzone, R., Vu Dinh, L., King, N. J. C., & Mahalingam, S. (2015) · Immunological Reviews · doi:10.1111/imr.12367 · Cited by 255
Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses
Yang, Z.-Y., Werner, H. C., Kong, W.-P., Leung, K., Traggiai, E., Lanzavecchia, A., & Nabel, G. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409065102 · Cited by 253
Yasui, F., Kai, C., Kitabatake, M., Inoue, S., Yoneda, M., Yokochi, S., Kase, R., Sekiguchi, S., Morita, K., Hishima, T., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.9.6337 · Cited by 252
Structure-Based Vaccine Antigen Design
Graham, B. S., Gilman, M. S. A., & McLellan, J. S. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-121217-094234 · Cited by 234
Nguyen-Contant, P., Embong, A. K., Kanagaiah, P., Chaves, F. A., Yang, H., Branche, A. R., Topham, D. J., & Sangster, M. Y. (2020) · mBio · doi:10.1128/mbio.01991-20 · Cited by 204
“235 However, a protective function for anti-N Abs has not been established (21).”
BackgroundWang, L., Shi, W., Chappell, J. D., Joyce, M. G., Zhang, Y., Kanekiyo, M., Becker, M. M., van Doremalen, N., Fischer, R., Wang, N., et al. (2018) · Journal of Virology · doi:10.1128/jvi.02002-17 · Cited by 169
Microstructure, pathophysiology, and potential therapeutics of COVID‐19: A comprehensive review
Singh, S. P., Pritam, M., Pandey, B., & Yadav, T. P. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26254 · Cited by 166
“humoral and cellular immune responses in C57BL/6 mice and was effective in viral clearance from the lungs(127-129) but contradictory results were obtained in hamsters.(130)”
ResultCurrent advances in the development of SARS-CoV-2 vaccines
Awadasseid, A., Wu, Y., Tanaka, Y., & Zhang, W. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.52569 · Cited by 164
He, Y., Li, J., Heck, S., Lustigman, S., & Jiang, S. (2006) · Journal of Virology · doi:10.1128/jvi.00083-06 · Cited by 135
Coughlin, M., Lou, G., Martinez, O., Masterman, S. K., Olsen, O. A., Moksa, A. A., Farzan, M., Babcook, J. S., & Prabhakar, B. S. (2007) · Virology · doi:10.1016/j.virol.2006.09.029 · Cited by 70
Bai, B., Hu, Q., Hu, H., Zhou, P., Shi, Z., Meng, J., Lu, B., Huang, Y., Mao, P., & Wang, H. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002685 · Cited by 59
Hennrich, A. A., Sawatsky, B., Santos-Mandujano, R., Banda, D. H., Oberhuber, M., Schopf, A., Pfaffinger, V., Wittwer, K., Riedel, C., Pfaller, C. K., et al. (2021) · PLOS Pathogens · doi:10.1371/journal.ppat.1009064 · Cited by 30
Metadata
- Authors
- Buchholz, U. J., Bukreyev, A., Yang, L., Lamirande, E. W., Murphy, B. R., Subbarao, K., & Collins, P. L.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2004-06-21
- Volume
- 101
- Issue
- 26
- Pages
- 9804-9809
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2016685455
- Cited by
- 385
- References
- 27
- FWCI
- 18.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.